Baker Brothers Advisors - Q1 2023 holdings

$18.4 Billion is the total value of Baker Brothers Advisors's 105 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .

 Value Shares↓ Weighting
BGNE  BeiGene, Ltd.sponsored adr$2,514,997,370
-2.0%
11,668,8970.0%13.68%
-11.2%
MDGL  Madrigal Pharmaceuticals, Inc.$374,319,075
-16.5%
1,545,1130.0%2.04%
-24.4%
IMCR  Immunocore Holdings plcads$124,624,941
-13.4%
2,520,7310.0%0.68%
-21.5%
KOD  Kodiak Sciences Inc.$107,325,038
-13.4%
17,310,4900.0%0.58%
-21.5%
BCRX  BioCryst Pharmaceuticals, Inc.$106,008,222
-27.4%
12,710,8180.0%0.58%
-34.1%
ARGX  argenx SEsponsored adr$104,381,640
-1.6%
280,1590.0%0.57%
-10.8%
AKRO  Akero Therapeutics, Inc.$90,614,142
-30.2%
2,368,3780.0%0.49%
-36.7%
KYMR  Kymera Therapeutics, Inc.$85,329,215
+18.7%
2,879,8250.0%0.46%
+7.4%
REPL  Replimune Group, Inc.$80,852,425
-35.1%
4,578,2800.0%0.44%
-41.2%
ABCL  AbCellera Biologics Inc.$78,794,357
-25.6%
10,450,1800.0%0.43%
-32.5%
 Entrada Therapeutics, Inc.$70,554,376
+7.2%
4,865,8190.0%0.38%
-2.8%
PRLD  Prelude Therapeutics Inc.$57,705,797
-5.6%
10,123,8240.0%0.31%
-14.4%
MRTX  Mirati Therapeutics, Inc.$52,415,769
-17.9%
1,409,7840.0%0.28%
-25.8%
CERS  Cerus Corporation$47,720,647
-18.6%
16,067,5580.0%0.26%
-26.1%
IMTX  Immatics N.V.$35,790,859
-20.8%
5,187,0810.0%0.20%
-28.0%
NRIX  Nurix Therapeutics, Inc.$34,473,270
-19.1%
3,882,1250.0%0.19%
-26.6%
KNSA  Kiniksa Pharmaceuticals, Ltd.$30,123,449
-28.2%
2,799,5770.0%0.16%
-34.9%
XENE  Xenon Pharmaceuticals Inc.$26,901,160
-9.2%
751,6390.0%0.15%
-18.0%
DNLI  Denali Therapeutics Inc.$25,084,524
-17.2%
1,088,7380.0%0.14%
-25.3%
DBVT  DBV Technologies S.A.sponsored adr$24,698,106
+10.5%
14,614,2640.0%0.13%0.0%
KRYS  Krystal Biotech, Inc.$24,235,443
+1.1%
302,7160.0%0.13%
-8.3%
VERV  Verve Therapeutics, Inc.$20,426,363
-25.5%
1,416,5300.0%0.11%
-32.7%
RARE  Ultragenyx Pharmaceutical Inc.$18,886,057
-13.4%
470,9740.0%0.10%
-21.4%
BCYC  Bicycle Therapeutics plcsponsored ads$17,947,924
-28.1%
843,8140.0%0.10%
-34.7%
ANAB  AnaptysBio, Inc.$16,884,106
-29.8%
775,9240.0%0.09%
-36.1%
SBTX  ARS Pharmaceuticals, Inc.$13,061,996
-23.7%
2,006,4510.0%0.07%
-31.1%
PACB  Pacific Biosciences of California, Inc.$13,059,716
+41.6%
1,127,7820.0%0.07%
+29.1%
 Prime Medicine, Inc.$12,650,132
-33.8%
1,028,4660.0%0.07%
-40.0%
HRTX  Heron Therapeutics, Inc.$12,278,834
-39.6%
8,131,6780.0%0.07%
-45.1%
CABA  Cabaletta Bio, Inc.$11,114,880
-10.6%
1,344,0000.0%0.06%
-20.0%
OPT  Opthea Limitedsponsored ads$10,630,994
-26.3%
2,691,3910.0%0.06%
-33.3%
ADAP  Adaptimmune Therapeutics plcsponsored adr$10,715,656
-25.3%
9,830,8770.0%0.06%
-32.6%
PNT  POINT Biopharma Global Inc.$8,499,379
-0.3%
1,169,1030.0%0.05%
-9.8%
BLUE  bluebird bio, Inc.$7,949,094
-54.0%
2,499,7150.0%0.04%
-58.7%
 Aadi Bioscience, Inc.$7,167,079
-43.6%
989,9280.0%0.04%
-48.7%
MGNX  MacroGenics, Inc.$6,399,791
+6.9%
892,5790.0%0.04%
-2.8%
ARAV  Aravive, Inc.$6,522,448
+51.5%
3,261,2240.0%0.04%
+34.6%
 TScan Therapeutics, Inc.$5,848,063
+35.5%
2,784,7920.0%0.03%
+23.1%
NTRA  Natera, Inc.$5,552,000
+38.2%
100,0000.0%0.03%
+25.0%
CMPX  Compass Therapeutics, Inc.$5,093,450
-35.0%
1,557,6300.0%0.03%
-40.4%
AFMD  Affimed N.V.$4,918,596
-39.9%
6,596,8300.0%0.03%
-44.9%
BCEL  Atreca, Inc.$4,027,346
+42.4%
3,532,7600.0%0.02%
+29.4%
IPSC  Century Therapeutics, Inc.$3,988,210
-32.4%
1,149,3400.0%0.02%
-37.1%
TLIS  Talis Biomedical Corporation$3,736,169
+9.9%
7,624,8350.0%0.02%0.0%
XNCR  Xencor, Inc.$3,434,012
+7.1%
123,1270.0%0.02%0.0%
TIL  Instil Bio, Inc.$3,484,920
+4.9%
5,273,7890.0%0.02%
-5.0%
EWTX  Edgewise Therapeutics, Inc.$3,335,000
-25.4%
500,0000.0%0.02%
-33.3%
 Tango Therapeutics, Inc.$2,962,500
-45.5%
750,0000.0%0.02%
-51.5%
NLTX  Neoleukin Therapeutics, Inc.$2,675,218
+37.5%
3,821,7400.0%0.02%
+25.0%
HOOK  HOOKIPA Pharma Inc.$2,557,994
-9.1%
3,475,5350.0%0.01%
-17.6%
VERA  Vera Therapeutics, Inc.cl a$2,586,664
-59.9%
333,3330.0%0.01%
-64.1%
ACHL  Achilles Therapeutics plcsponsored ads$2,481,233
+6.4%
2,591,3660.0%0.01%
-7.1%
ATRA  Atara Biotherapeutics, Inc.$2,158,139
-11.6%
744,1860.0%0.01%
-20.0%
ITOS  iTeos Therapeutics, Inc.$2,046,209
-30.3%
150,3460.0%0.01%
-38.9%
PCVX  Vaxcyte, Inc.$1,832,210
-21.8%
48,8850.0%0.01%
-28.6%
ALGS  Aligos Therapeutics, Inc.$1,814,774
-8.3%
2,076,4000.0%0.01%
-16.7%
VERU  Veru Inc.$1,867,112
-78.0%
1,609,5790.0%0.01%
-80.4%
PMVP  PMV Pharmaceuticals, Inc.$1,536,054
-45.2%
322,0240.0%0.01%
-52.9%
NKTX  Nkarta, Inc.$1,420,000
-40.7%
400,0000.0%0.01%
-42.9%
TCRR  TCR2 Therapeutics Inc.$1,129,596
+50.2%
753,0640.0%0.01%
+20.0%
 Kala Pharmaceuticals, Inc.$1,156,036
-60.6%
76,8130.0%0.01%
-66.7%
AGLE  Aeglea BioTherapeutics, Inc.$988,931
-35.5%
3,410,1060.0%0.01%
-44.4%
TARA  Protara Therapeutics, Inc.$624,970
+16.8%
199,6710.0%0.00%0.0%
GTH  Genetron Holdings Limitedads$478,071
-6.3%
455,3060.0%0.00%0.0%
FHTX  Foghorn Therapeutics Inc.$279,167
-2.8%
45,0270.0%0.00%0.0%
VINC  Vincerx Pharma, Inc.$251,034
+2.0%
241,3790.0%0.00%0.0%
 Bellicum Pharmaceuticals, Inc.$82,211
-54.2%
249,1230.0%0.00%
-100.0%
 Surrozen, Inc.w exp 8/11/2026$83,333
+81.5%
833,3330.0%0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation42Q3 202337.6%
ACADIA Pharmaceuticals Inc.42Q3 202310.9%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
BioCryst Pharmaceuticals, Inc.42Q3 20231.7%
Cerus Corporation42Q3 20230.9%
Insmed Incorporated42Q3 20230.4%
Mirati Therapeutics, Inc.41Q3 20231.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
ChemoCentryx, Inc.37Q3 20220.6%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.August 17, 20239,469,83820.0%
Mereo Biopharma Group plcAugust 10, 202314,604,3912.2%
Verastem, Inc.August 10, 2023? ?
TScan Therapeutics, Inc.June 02, 20232,793,9386.5%
ACADIA PHARMACEUTICALS INCMay 24, 202343,084,28026.5%
INCYTE CORPMarch 15, 202336,280,96716.3%
Seagen Inc.March 13, 202346,985,65625.1%
Talis Biomedical CorpMarch 10, 202337,569,14066.2%
Aeglea BioTherapeutics, Inc.February 14, 20236,384,0139.9%
Merus N.V.February 14, 2023? ?

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-23
SC 13D/A2024-04-23
42024-04-22
32024-04-18
SC 13D2024-04-18
32024-04-01
42024-04-01
42024-04-01
42024-04-01
SC 13D2024-04-01

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings